{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T15:09:21Z","timestamp":1788793761596,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100024990","name":"National Yang Ming Chiao Tung University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100024990","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Since 2011, the Taiwan Food and Drug Administration (TFDA) has established various facilitated regulatory pathways (FRPs, including expedited and accelerated review frameworks) for new drug applications. In 2017 and 2019, TFDA implemented the Refuse to File (RTF) mechanism and conducted a comprehensive revision of FRPs, respectively. This study aims to evaluate the outcomes of these reforms from 2015 to 2024, focusing on New Active Substance (NAS) approvals, pathway utilization, and international comparison.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>NAS approvals between 2015 and 2024 were analyzed using TFDA\u2019s internal regulatory database, with U.S. Food and Drug Administration (US FDA), European Medicines Agency (EMA), and Japan\u2019s Pharmaceuticals and Medical Devices Agency (Japan\u2019s PMDA) data obtained from public sources. Analyses and visualizations were conducted with R.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Following the 2017 and 2019 reforms, the on-time rate for the 360-day standard pathway surged from 19.0% of 21 cases in 2015 to 100% in 16 cases in 2024. A distinct structural shift toward FRPs was observed, as the proportion of standard applications declined from 80.4% to 56.4%. A contextual comparison of median approval times indicated that TFDA\u2019s timelines were broadly comparable to those of the EMA and moved closer to those of the US FDA and Japan\u2019s PMDA over the study period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The TFDA review timelines became substantially more predictable, and the pathway distribution shifted toward FRPs. These changes followed the 2017 and 2019 reforms and reflect their combined contribution rather than any single mechanism. The cross-agency figures reported here serve as a general point of reference rather than a direct efficiency comparison, given differences in product mix, therapeutic areas, pathway eligibility criteria, submission timing and clock-stop mechanisms. Building on these developments, the forthcoming reliance pilot program is expected to further support patient access and regulatory resilience.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s43441-026-01038-3","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:07:57Z","timestamp":1788275277000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Review Performance of New Active Substances in Taiwan: A 10-Year Retrospective Analysis (2015\u20132024)"],"prefix":"10.1007","author":[{"given":"Chun-Yi","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Kuei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bi-Kai","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwei-Fang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Hsuen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"1038_CR1","unstructured":"Laws and Regulations Database of Taiwan. Regulations for registration of medicinal products, Article 39. Available from: https:\/\/law.moj.gov.tw\/ENG\/LawClass\/LawAll.aspx?pcode=L0030057"},{"key":"1038_CR2","unstructured":"Centre for Innovation in Regulatory Science. (August 6, 2025). CIRS RD Briefing 101: New drug approvals by six major authorities, 2015\u20132024. Available from: https:\/\/www.cirsci.org\/publications\/cirs-rd-briefing-101-new-drug-approvals-by-six-major-authorities-2015-2024\/"},{"key":"1038_CR3","unstructured":"US Food and Drug Administration, Track F, Therapy B, Approval A. Priority Review. Available from: https:\/\/www.fda.gov\/patients\/learn-about-drug-and-device-approvals\/fast-track-breakthrough-therapy-accelerated-approval-priority-review"},{"key":"1038_CR4","unstructured":"European Commission. EudraLex\u2014Volume 1\u2014Pharmaceutical legislation for medicinal products for human use. Regulation (EC) No 726\/2004 of the European Parliament and of the Council of 31 March 2004 laying down community procedures for the authorization and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. Available from: https:\/\/eur-lex.europa.eu\/eli\/reg\/2004\/726\/2019-01-28."},{"key":"1038_CR5","unstructured":"European Commission. EudraLex\u2014Volume 1\u2014Pharmaceutical legislation for medicinal products for human use. Commission Regulation (EC) No 507\/2006 of 29 March 2006 on the conditional marketing authorisation for medicinal products for human use falling within the scope of Regulation (EC) No 726\/2004 of the European Parliament and of the Council. Available from: https:\/\/eur-lex.europa.eu\/eli\/reg\/2006\/507\/oj"},{"key":"1038_CR6","unstructured":"European Medicines Agency. Guideline on the scientific application and the practical arrangements necessary to implement the procedure for accelerated assessment pursuant to Article 14(9) of Regulation (EC) No 726\/2004. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-scientific-application-and-practical-arrangements-necessary-implement-procedure-accelerated-assessment-pursuant-article-149-regulation-ec-no-7262004_en.pdf"},{"key":"1038_CR7","unstructured":"European Medicines Agency. Guideline on the scientific application and the practical arrangements necessary to implement Commission Regulation (EC) No 507\/2006 on the conditional marketing authorization for medicinal products for human use falling within the scope of Regulation (EC) No 726\/2004. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/draft-guideline-scientific-application-and-practical-arrangements-necessary-implement-regulation-ec-no-507-2006-conditional-marketing-authorisation-medicinal-products-human-use-falling_en.pdf"},{"key":"1038_CR8","unstructured":"European Medicines Agency. Enhanced early dialogue to facilitate accelerated assessment of Priority Medicines (PRIME). Available from: https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/enhanced-early-dialogue-facilitate-accelerated-assessment-priority-medicines-prime_en.pdf"},{"issue":"15","key":"1038_CR9","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.3390\/ijms20153801","volume":"20","author":"S Nagai","year":"2019","unstructured":"Nagai S. Flexible and expedited regulatory review processes for innovative medicines and regenerative medical products in the US, the EU, and Japan. Int J Mol Sci. 2019;20(15):3801.","journal-title":"Int J Mol Sci"},{"key":"1038_CR10","unstructured":"Ministry of Health, Labour and Welfare (Japan). Sakigake drug designation system. Available from: https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/kenkou_iryou\/iyakuhin\/tp150514-01_00001.html"},{"key":"1038_CR11","unstructured":"Taiwan Food and Drug Administration. (March 1, 2011). Announcement of the Abbreviated Review and Priority Review. No. 0991416281. Available from: https:\/\/regulation.cde.org.tw\/10254\/4045\/40672\/"},{"key":"1038_CR12","unstructured":"Taiwan Food and Drug Administration. (August 14, 2013). Announcement of the Accelerated Approval. No. 1021404509. Available from: https:\/\/regulation.cde.org.tw\/10254\/4045\/41052\/"},{"key":"1038_CR13","unstructured":"Taiwan Food and Drug Administration. (February 12, 2018). Announcement of the Breakthrough Therapy Designation. No. 1061011629A. Available from: https:\/\/regulation.cde.org.tw\/10254\/4045\/41614\/"},{"key":"1038_CR14","unstructured":"Taiwan Food and Drug Administration. (November 18, 2019). Announcement of the Pediatric and Rare Severe Disease Priority Review Voucher Program and amendment of the New Drug Streamlined Review Mechanism, Abbreviated Review, Priority Review, Accelerated Approval, and Breakthrough Therapy Designation. No. 1081410630. Available from: https:\/\/www.fda.gov.tw\/tc\/siteListContent.aspx?sid=2984&id=32228"},{"key":"1038_CR15","unstructured":"World Health Organization. (2021). Good reliance practices in the regulation of medical products: High level principles and considerations (WHO Technical Report Series, No. 1033, Annex 10). Available from: https:\/\/cdn.who.int\/media\/docs\/default-source\/medicines\/norms-and-standards\/guidelines\/inspections\/grelp-annex-10-trs-1033\/trs1033_annex10-good-reliance-practices.pdf?sfvrsn=dd5502cb_17&download=true"},{"key":"1038_CR16","unstructured":"World Health Organization. (2023). WHO-listed authorities: Regulatory authorities. Available from: https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/58d7a8e4-49ac-4476-a9e4-91dda98cdce5\/content"},{"key":"1038_CR17","unstructured":"Laws and Regulations Database of Taiwan. Regulations for Registration of Medicinal Products, Article 38\u2009\u2013\u20095. Available from: https:\/\/law.moj.gov.tw\/ENG\/LawClass\/LawAll.aspx?pcode=L0030057"},{"key":"1038_CR18","first-page":"30","volume":"74","author":"CJ Wang","year":"2016","unstructured":"Wang CJ. Announcement of the Refuse to File (RTF) mechanism for new drug registration. Contemp Regul Med. 2016;74:30.","journal-title":"Contemp Regul Med"},{"key":"1038_CR19","unstructured":"aiwan Food and Drug Administration. (September 20, 2018). FDA Yao Zi No. 1071408056. Available from: https:\/\/regulation.cde.org.tw\/10254\/4045\/54149\/regPost"},{"key":"1038_CR20","unstructured":"Taiwan Food and Drug Administration. (January 8, 2024). Wei Shou Shi Zi No. 1121414699. Available from: https:\/\/regulation.cde.org.tw\/10254\/4045\/55539\/regPost"},{"key":"1038_CR21","unstructured":"Center for Drug Evaluation and Research, US Food and Drug Administration. Good review practice: refuse to file. Manual of Policies and Procedures (MAPP) 6025.4, Rev. 1. Available from: https:\/\/www.fda.gov\/media\/87035\/download"},{"key":"1038_CR22","unstructured":"Huang YC. Introduction to new measures for the management of new drug applications. Contemporary regulatory medicine (RegMed), 2019, 102, 1\u201312. Available from: https:\/\/www.cde.org.tw\/media\/3p3ntayl\/64b39f04-094c-49b2-98cd-5279575f430c.pdf?mediaDL=true"},{"issue":"6","key":"1038_CR23","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s10198-023-01639-x","volume":"25","author":"DT Michaeli","year":"2024","unstructured":"Michaeli DT, Michaeli T, Albers S, et al. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy. Eur J Health Econ. 2024;25(6):979\u201397.","journal-title":"Eur J Health Econ"},{"issue":"1","key":"1038_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/qjmed\/hcae115","volume":"118","author":"H Hakariya","year":"2025","unstructured":"Hakariya H, Ozaki A, Mulinari S, et al. Evaluating time to withdrawal of anti-cancer drug indications that received FDA\u2019s accelerated approval. QJM: Int J Med. 2025;118(1):3\u20134.","journal-title":"QJM: Int J Med"},{"issue":"5","key":"1038_CR25","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1111\/bcp.16385","volume":"91","author":"V Del Grosso","year":"2025","unstructured":"Del Grosso V, Perini M, Casilli G, et al. Performance of the accelerated assessment of the European Medicines Agency. Br J Clin Pharmacol. 2025;91(5):1439\u201348.","journal-title":"Br J Clin Pharmacol"},{"key":"1038_CR26","doi-asserted-by":"publisher","first-page":"1623689","DOI":"10.3389\/fmed.2025.1623689","volume":"12","author":"S Alaburde","year":"2025","unstructured":"Alaburde S, Ivaska J, Kaspute G, et al. Impact of regulatory measures on the approval timelines of advanced therapy medicinal products by the European Medicines Agency. Front Med. 2025;12:1623689.","journal-title":"Front Med"},{"key":"1038_CR27","unstructured":"Laws and Regulations Database of Taiwan. Pharmaceutical Affairs Act Enforcement Rules, Article 2. Available from: https:\/\/law.moj.gov.tw\/ENG\/LawClass\/LawAll.aspx?pcode=L0030002"},{"key":"1038_CR28","unstructured":"Centre for Innovation in Regulatory Science. (May 16, 2016). CIRS RD Briefing 59: New approvals in six regulatory authorities 2006\u20132015 Available from: https:\/\/cirsci.org\/publications\/cirs-rd-briefing-59-new-approvals-in-six-regulatory-authorities-2006-2015\/"},{"key":"1038_CR29","unstructured":"Centre for Innovation in Regulatory Science. (November 20, 2017). CIRS RD Briefing 65: New approvals in six regulatory authorities 2007\u20132016. Available from: https:\/\/cirsci.org\/publications\/cirs-rd-briefing-65-new-approvals-in-six-regulatory-authorities-2007-2016\/"},{"key":"1038_CR30","unstructured":"Centre for Innovation in Regulatory Science. (May 4, 2018). CIRS RD Briefing 67: New approvals in six regulatory authorities 2008\u20132017. Available from: https:\/\/cirsci.org\/publications\/cirs-rd-briefing-67-new-approvals-in-six-regulatory-authorities-2008-2017\/"},{"key":"1038_CR31","unstructured":"Centre for Innovation in Regulatory Science. (May 13, 2019). CIRS RD Briefing 70: New approvals in six regulatory authorities 2009\u20132018. Available from: https:\/\/cirsci.org\/publications\/cirs-rd-briefing-70-new-approvals-in-six-regulatory-authorities-2009-18\/"},{"key":"1038_CR32","unstructured":"Centre for Innovation in Regulatory Science. (June 1, 2020). CIRS RD Briefing 77: N New drug approvals in six major authorities 2010\u20132019. Available from: https:\/\/cirsci.org\/publications\/cirs-rd-briefing-77-new-drug-approvals-in-six-major-authorities\/"},{"key":"1038_CR33","unstructured":"Centre for Innovation in Regulatory Science. (July 7, 2021). CIRS RD Briefing 81: New drug approvals in six major authorities 2011\u20132020. Available from: https:\/\/cirsci.org\/publications\/cirs-rd-briefing-81-new-drug-approvals-in-six-major-authorities-2011-2020\/"},{"key":"1038_CR34","unstructured":"Centre for Innovation in Regulatory Science. (July 28, 2022). CIRS RD Briefing 85: New drug approvals in six major authorities 2012\u20132021. Available from: https:\/\/www.cirsci.org\/publications\/cirs-rd-briefing-85-new-drug-approvals-in-six-major-authorities-2012-2021\/"},{"key":"1038_CR35","unstructured":"Centre for Innovation in Regulatory Science. (July 3, 2023). CIRS RD Briefing 88: New drug approvals in six major authorities 2013\u20132022: Focus on orphan designation and facilitated regulatory pathways. Available from: https:\/\/www.cirsci.org\/publications\/cirs-rd-briefing-88-new-drug-approvals-in-six-major-authorities-2013-2022-focus-on-orphan-designation-and-facilitated-regulatory-pathways\/"},{"key":"1038_CR36","unstructured":"Centre for Innovation in Regulatory Science. (July 9, 2024). CIRS RD Briefing 93: New drug approvals by six major authorities 2014\u20132023. Available from: https:\/\/cirsci.org\/publications\/cirs-rd-briefing-93-new-drug-approvals-by-six-major-authorities-2014-2023\/"},{"issue":"1","key":"1038_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/17512433.2022.2037419","volume":"15","author":"A Vaz","year":"2022","unstructured":"Vaz A, Rold\u00e3o Santos M, Gwaza L, et al. WHO collaborative registration procedure using stringent regulatory authorities\u2019 medicine evaluation: reliance in action? Expert Rev Clin Pharmacol. 2022;15(1):11\u20137.","journal-title":"Expert Rev Clin Pharmacol"}],"updated-by":[{"DOI":"10.1007\/s43441-026-01042-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000}}],"container-title":["Therapeutic Innovation &amp; Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-01038-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-026-01038-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-01038-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:25:46Z","timestamp":1788791146000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43441-026-01038-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":37,"alternative-id":["1038"],"URL":"https:\/\/doi.org\/10.1007\/s43441-026-01038-3","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"assertion":[{"value":"10 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s43441-026-01042-7","URL":"https:\/\/doi.org\/10.1007\/s43441-026-01042-7","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}